Clicky

ALX Oncology Holdings Inc.(ALXO) News

Date Title
May 14 Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet
May 10 ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...
May 9 ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 7 ALX Oncology Appoints Allison Dillon as Chief Business Officer
Apr 30 ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
Apr 24 ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
Apr 15 Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
Apr 11 ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
Apr 9 ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
Apr 6 ALX Oncology Holdings Inc (ALXO) Insider Sells Shares
Mar 8 ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer
Mar 8 ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending
Mar 7 ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Mar 5 ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
Nov 13 ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments
Nov 13 ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 1 ALX Oncology Announces November Investor Conference Participation
Aug 31 ALX Oncology Announces September Investor Conference Participation
Apr 25 ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma